Table 1. Known interactions of LNX1/2 proteins.

Interacting protein	Description/function	Binds to:	Domain(s) involved	Methods used	Substrate for ubiquitination	References
NUMB	Cell fate determinant	LNX1, LNX2	NPAY/F, PDZ1	Y2H, GST-PD, Co-IP(h)	Yes; proteasomal degradation	[3,4,6,10,11]
NUMB-like	Cell fate determinant	LNX1, LNX2	NPAY/F motif	Y2H, GST-PD, Co-IP(h)	n/d	[3,6]
SHOOTIN	Polarity protein	LNX1, LNX2	PDZ2,3,4	Protein array, Co-IP(h,e)	n/d	[46]
CASPR4	Neurexin family protein	LNX2	PDZ2	Y2H, GST-PD, Co-IP(h), Co-L	n/d	[45]
CLAUDIN-1, 2, 17	Tight junction	LNX1	PDZ1, PDZ2	Y2H, GST-PD, Co-IP(h)	Yes; endocytosis	[9,51]
JAM4	Tight junction	LNX1	PDZ2	Y2H, Co-IP(h), Co-local	n/d	[39]
CAR	Tight junction	LNX1, LNX2	PDZ2	Y2H, GST-PD, Co-IP(h)	n/d	[30,36,52]
ERC1, ERC2	Presynaptic	LNX1, LNX2	PDZ2	Y2H, Co-IP(h), GFP-PD, Co-L	Yes	[13,14,56]
LIPRIN-α1, -α3	Presynaptic	LNX1, not -2	PDZ2	Co-IP(h) GFP-PD	Yes; not degraded	[13,14]
ERBB2	Receptor Tyrosine kinase	LNX1	PDZ1-4	Y2H, Co-IP (h,e)	n/d	[33]
CD8-α	T-cell co-receptor	LNX1, LNX2	PDZ1/2	Y2H, Co-IP(e), GST-PD, Co-L	Yes; lysosomal degradation	[29]
KCNA4	K+ channel	LNX1, LNX2	PDZ1	Y2H, Co-IP(h)	n/d	[15,18]
EPHA7	Receptor Tyrosine kinase	LNX1, LNX2	PDZ1-4	Y2H, GFP-PD	n/d	[1,14,50]
Bozozok	Transcription factor	LNX2b	n/d	Co-IP(h)	Yes; degradation	[69]
E4F1	Transcription factor	LNX1, -2, -2b	n/d	Co-IP(h), GST-PD	Yes; not degraded	[71]
TCF3	Transcription factor	LNX2b	n/d	Co-IP(h)	n/d	[71]
TLE3	Transcription factor	LNX2b	n/d	Co-IP(h)	n/d	[71]
HDAC1	Histone deactylase	LNX2b	n/d	Co-IP(h)	n/d	[71]
NP9	Nuclear protein	LNX1	PDZ2-4	Y2H, GST-PD, Co-L	n/d	[58]
SKIP	Nuclear protein	LNX1	n/d	Y2H, Co-IP(h), Co-L	n/d	[61]
HOXA1	Transcription factor	LNX2	n/d	Y2H, Co-IP(h), BiFC	n/d	[63]
KLHL11	Kelch-like	LNX1, LNX2	PDZ2	GFP-PD	Yes	[14]
KIF7	Kinesin	LNX1, not -2	PDZ1-4	GFP-PD	Yes	[14]
SYNGAP1	GTPase activating protein	LNX1, LNX2	PDZ1, PDZ2	Y2H, GFP-PD	n/d	[1,14]
SRGAP2	GTPase activating protein	LNX1, LNX2	PDZ2	GFP-PD	Yes (weak)	[13,14]
MID2	Ubiquitin ligase	LNX1, not -2	PDZ1-4	GFP-PD	n/d	[14]
AKAP13	Scaffold protein	LNX1, not -2	PDZ2	GFP-PD	n/d	[14]
PBK	MAP kinase kinase	LNX1, LNX2	PDZ1 or PDZ1-4	Y2H, Co-IP(h)	Yes; proteasomal degradation	[9,15,18]
BCR	GTPase activating protein	LNX1	PDZ3	Y2H	Yes, proteasomal degradation	[9]
c-SRC	Tyrosine kinase	LNX1	PDZ3, PDZ1	PDZ array, Co-IP(h,e), Co-L	Yes, proteasomal degradation	[31]
RHO-C	GTPase	LNX1	PDZ1	Y2H, Co-IP(h), Co-L	n/d	[59]
PAK6	Ser/Thr kinase	LNX, LNX2	PDZ2,4	Y2H, Co-IP(h)	n/d	[15,18]
PLEKHG5	RhoGEF protein	LNX1, LNX2	PDZ1,3	ProtoArray, Co-IP(h)	n/d	[18]
PKCα	Ser/Thr kinase	LNX1, LNX2	PDZ2,4	Peptide Array, Co-IP(h)	n/d	[18,50]
TYK2	Non-receptor Tyrosine kinase	LNX1, LNX2	PDZ2	Y2H, Co-IP(h)	n/d	[15,18]
RNase-L	Endoribonuclease	LNX1	PDZ1-4	Y2H, Co-IP(h)	No	[84]
MAGEB18	Tumour antigen	LNX1	-	TAP, Co-IP(h)	n/d	[66]

Only interactions that have been verified using full-length proteins expressed in mammalian cells are listed. For interacting proteins that are LNX1/2 substrates, the consequence of ubiquitination is stated (if known). Abbreviations: BCR, breakpoint cluster region protein; Co-IP(h) or Co-IP(e), co-immunoprecipitation of heterologously expressed or endogenous proteins respectively; Co-L, co-localization in cells or tissues; GFP-PD or GST-PD, ‘pull down’ experiment using a GFP or GST tag respectively; n/d, not determined; PBK, PDZ-binding kinase; SKIP, Ski interacting protein; Y2H, yeast two-hybrid.